The electrolytic induction of endothelial activation to the internal surface of the Inferior Vena Cava results in venous type thrombus formation due to endothelial activation and partial blood stasis, two components of Virchow’s triad.
Animal models serve a vital role in deep venous thrombosis (DVT) research in order to study thrombus formation, thrombus resolution and to test potential therapeutic compounds (1). New compounds to be utilized in the treatment and prevention of DVT are currently being developed. The delivery of potential therapeutic antagonist compounds to an affected thrombosed vein has been problematic. In the context of therapeutic applications, a model that uses partial stasis and consistently generates thrombi within a major vein has been recently established. The Electrolytic Inferior vena cava Model (EIM) is mouse model of DVT that permits thrombus formation in the presence of continuous blood flow. This model allows therapeutic agents to be in contact with the thrombus in a dynamic fashion, and is more sensitive than other models of DVT (1). In addition, this thrombosis model closely simulates clinical situations of thrombus formation and is ideal to study venous endothelial cell activation, leukocyte migration, venous thrombogenesis, and to test therapeutic applications (1). The EIM model is technically simple, easily reproducible, creates consistent thrombi sizes and allows for a large sample (i.e. thrombus and vein wall) which is required for analytical purposes.
1. Mouse Anesthesia Procedures
2. Mouse Micro-surgical and Recovery Procedures
3. Representative Results
The EIM is a model that forms thrombus in the presence of continuous blood flow. The following figures show parameters investigated in this novel model.
Figure 1 definesthe anatomical area in where a 25G stainless-steel needle, attached to a silver coated copper wire (KY-30-1-GRN, Electrospec, Dover, NJ) is inserted. Note that a lymphatic node is almost present and helps as a landmark to find the caudal IVC.
Figure 2: Thrombus weight 2 days after EIM in different strains. As expected, thrombus weight was lower in PAI-1 KO mice and larger in hypercoagulable Delta CT mice (^CT).
Figure 3: Soluble P-selectin, a maker for deep vein thrombosis, was measured in different strains. The lowest levels were found in PAI-1 KO mice whereas the highest levels were found in hypercoagulable delta CT mice.
Figure 4 Correlation between thrombus weight and soluble P-selectin was found in different strains. Of note, in the group that generated the shorter thrombus size, the soluble P-selectin detected was the lowest (PAI-1 KO mice). In the group that generated the largest thrombus size, the soluble P-selectin detected was the highest (hypercoagulable delta CT).
Figure 5: In order to demonstrate presence of blood flow, ultrasound was performed in mice undergoing EIM. Figure 5 shows the ultrasound performed in a mouse 2 days after EIM. Then the specimen was harvest. Note the that the thrombus shape suggest thrombus formation in presence of flow
The mouse is an excellent research tool for in vivo experiments. Thus, the development of mouse models that closely mimic diseases or pathological conditions are necessary. Several venous thrombosis mouse models have been used to study DVT including: photochemical (2), stasis (3-4) and mechanical trauma (5-6). However, none of these models use an internal endothelial stimulus to generate thrombus in the presence of continuous blood flow. The EIM, using electrolytic stimulus within the IVC, promotes venous thrombogenesis by endothelial activation in the presence of blood flow (1). It is technically simple, easily reproducible and has a high survival rate (99%). Despite the fact that an electrical current is used to create the electrolysis, heat is not generated (1). The EIM model closely simulates clinical DVT, and therefore serves as a valuable tool for studying the intrinsic mechanisms of thrombus formation and resolution. The EIM model is also useful for the advancement of new therapeutic approaches against thrombosis disease.
The authors have nothing to disclose.
Supported by NIH 1P01HL089407-01A1 (Lawrence, PI), Animal Core A,NIH 1 K01 HL080962-01A2 (Myers, PI).
Name of the reagent | Company | Catalogue number | Comments (optional) |
---|---|---|---|
DMEM | Invitrogen | ABCD1234 |